Haemonetics Corp. ( NYSE: HAE ) provides products for processing, handling and analysis of blood. Although COVID has pressured patient visits to infusion clinics for administration of IV therapy, the underlying illnesses being treated are all chronic conditions. The impact to plasma collections due to social distancing has only worked to further enhance the value proposition behind NexSys, which is also the only solution on the market that is proven to increase yields with each donation.